Honasa Consumer Limited has acquired a 58% majority stake in Fluence Pharma, marking its entry into the ₹16,000 crore nutraceuticals market. The move aims to expand its 'inside-out' beauty category.
Honasa Consumer Enters Nutraceuticals Market with Fluence Pharma Acquisition
Honasa Consumer Limited has acquired a 58% majority stake in Fluence Pharma, establishing a new subsidiary, Honasa Health Private Limited, to spearhead its expansion into the nutraceuticals market. The company views this move as a strategic step into the 'inside-out' beauty category.
What just happened
Honasa Consumer Limited has completed the acquisition of a 58% majority stake in Fluence Pharma. This strategic move involves the incorporation of a new subsidiary, Honasa Health Private Limited, to manage operations in the nutraceuticals sector. Fluence Pharma reported revenues of approximately ₹40 crore in FY26 with an EBITDA margin exceeding 20%.
Why this matters
This acquisition signifies Honasa Consumer's diversification into the rapidly growing nutraceuticals market, valued at over ₹16,000 crore. The company aims to leverage Fluence Pharma's patented 'Cyclical Nutrition Therapy' (CNT) and its network of dermatologists, combining it with Honasa's digital distribution and brand-building capabilities.
The backstory
Honasa Consumer is building a 'future-ready House of Brands.' This expansion into nutraceuticals is seen as a key component of that strategy. Fluence Pharma brings specialized clinical science and a practitioner network.
What changes now
A new subsidiary, Honasa Health Private Limited, will house the nutraceuticals business. Dheeraj Nagpal, with over 15 years of consumer business experience, will lead this subsidiary as CEO.
Risks to watch
Integration risk is a key concern. The success of this venture will depend on effectively merging Fluence Pharma's clinical and practitioner-led model with Honasa's digital-first direct-to-consumer (D2C) operations.
What looks positive
The acquisition brings a profitable target, as Fluence Pharma's reported 20%+ EBITDA margin is accretive to Honasa's business model. There is also strong strategic synergy, combining Honasa's distribution strengths with Fluence's specialized medical science and patented products.
What to track next
Investors will be keen to monitor the operational integration of Fluence Pharma's products into Honasa's digital network and track the revenue contribution of the new subsidiary in upcoming financial quarters.